Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
Trial Parameters
Brief Summary
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
Eligibility Criteria
Inclusion Criteria: * Refractory or unexplained chronic cough for ≥ 12 months. * Women of childbearing potential agree to follow the protocol specified contraceptive - guidance during the study. * Males who are not vasectomized must agree to use the contraceptive methods defined in the protocol. * Able to provide Informed Consent. Exclusion Criteria: * Previous exposure to taplucainium (formerly NTX-1175) or known allergy or hypersensitivity to taplucainium, its excipients/metabolites, or related compounds. * Participants who are currently participating in another drug or device clinical study * Participants who have participated in an Acute or Chronic Cough investigational study within 60 days before the start of the Screening. * Current diagnosis of chronic obstructive pulmonary disease, bronchiectasis, unexplained pulmonary fibrosis, hemoptysis, bronchial asthma, or other pulmonary disease. * Respiratory tract infection within 4 weeks of Screening or during screening period. * Any f